An inevitable wave of prescription drug monitoring programs in the context of prescription opioids: pros, cons and tensions

BMC Clinical Pharmacology

Ian S McRae¹  M Mofizul Islam¹ 

[1] Australian Primary Health Care Research Institute, Australian National University, Building 63, corner of Mills & Eggleston Roads, Canberra, ACTON ACT 0200, Australia

关键词: Prescription opioids;    Controlled drugs;    Prescription drugs;    Prescription drug monitoring programme;   

Others  :  1084832
DOI  :  10.1186/2050-6511-15-46

 received in 2014-04-25, accepted in 2014-08-06,  发布年份 2014

【 摘 要 】

Background

In an effort to control non-medical use and/or medical abuse of prescription drugs, particularly prescription opioids, electronic prescription drug monitoring programs (PDMP) have been introduced in North-American countries, Australia and some parts of Europe. Paradoxically, there are simultaneous pressures to increase opioid prescribing for the benefit of individual patients and to reduce it for the sake of public health, and this pressure warrants a delicate balance of appropriate therapeutic uses of these drugs with the risk of developing dependence. This article discusses pros and cons of PDMP in reducing diversion of prescription opioids, without hampering access to those medications for those with genuine needs, and highlights tensions around PDMP implementation.

Discussion

PDMPs may help alleviate diversion, over-prescription and fraudulent prescribing/dispensing; prompt drug treatment referrals; avoid awkward drug urine test; and inform spatial changes in prescribing practices and help designing tailored interventions. Fear of legal retribution, privacy and data security, potential confusion about addiction and pseudo-addiction, and potential undue pressure of detecting misuse/diversion - are the major problems. There are tensions about unintended consequence of excessive regulatory enforcements, corresponding collateral damages particularly about inadequate prescribing for patients with genuine needs, and mandatory consultation requirements of PDMP.

Summary

In this era of information technology PDMP is likely to flourish and remain with us for a long time. A clear standard of practice against which physicians’ care will be judged may expedite the utilisation of PDMP. In addition, adequate training on addiction and pain management along with public awareness, point-of-supply data entry from pharmacy, point-of-care real-time access to data, increasing access to addiction treatment and appropriate regulatory enforcement preferably through healthcare administration, together, may help remove barriers to PDMP use.

【 授权许可】

   
2014 Islam and McRae; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Wang J, Christo PJ: The influence of prescription monitoring programs on chronic pain management. Pain Physician 2009, 12(3):507-515.
• [2]Perrone J, Nelson LS: Medication reconciliation for controlled substances–an “ideal” prescription-drug monitoring program. N Engl J Med 2012, 366(25):2341-2343.
• [3]Paulozzi LJ, Kilbourne EM, Desai HA: Prescription drug monitoring programs and death rates from drug overdose. Pain Med 2011, 12(5):747-754.
• [4]Lembke A: Why doctors prescribe opioids to known opioid abusers. N Engl J Med 2012, 367(17):1580-1581.
• [5]Katz MH: Long-term opioid treatment of nonmalignant pain: a believer loses his faith. Arch Intern Med 2010, 170(16):1422-1424.
• [6]Office of Substance Abuse and Mental Health Services: 2013 Prescription Monitoring Program Survey Results. USA: Maine Department of Health and Human Services; 2013.
• [7]Baehren DF, Marco CA, Droz DE, Sinha S, Callan EM, Akpunonu P: A statewide prescription monitoring program affects emergency department prescribing behaviors. Ann Emerg Med 2010, 56(1):19-23. e11-13
• [8]Yokell MA, Green TC, Rich JD: Prescription drug monitoring programs. JAMA 2012, 307(9):912. author reply 912–913
• [9]Fishman SM: Commentary in Response To Paulozzi et al.: prescription drug abuse and safe pain management. Pharmacoepidemiol Drug Saf 2006, 15:628-631.
• [10]Fishman SM, Heit H, Covington E, Passik SD, Rich BA, Bolen J, Rowe W: The DEA and pain medicine-commentary series. Pain Med 2006, 7(1):71-88.
• [11]Turk DC, Brody MC, Okifuji EA: Physicians’ attitudes and practices regarding the long-term prescribing of opioids for non-cancer pain. Pain 1994, 59(2):201-208.
• [12]Institute of Medicine: Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. Washington, DC: The National Academies Press; 2011.
• [13]Ross-Degnan D, Simoni-Wastila L, Brown JS, Gao X, Mah C, Cosler LE, Fanning T, Gallagher P, Salzman C, Shader RI, Inui TS, Soumerai SB: A controlled study of the effects of state surveillance on indicators of problematic and non-problematic benzodiazepine use in a Medicaid population. Int J Psychiatry Med 2004, 34(2):103-123.
• [14]Nist JB: Liability for overprescription of controlled substances. Can it be justified in light of the current practice of undertreating pain? J Leg Med 2002, 23(1):85-113.
• [15]Finklea KM, Bagalman E, Sacco LN: Prescription Drug Monitoring Programs. Congressional Research Service; 2013. Available at: http://www.fas.org/sgp/crs/misc/R42593.pdf webcite
• [16]Brushwood DB: Maximizing the value of electronic prescription monitoring programs. J Law Med Ethics 2003, 31(1):41-54.
• [17]Cook L, Sefcik E, Stetina P: Pain management in the addicted population: A case study comparison of prescriptive practice. J Addict Nurs 2004, 15:11-14.
• [18]Nielsen S, Bruno R: Pharmacuetical drugs: The delicate balance between reducing pain and reducing harm. Drug Alcohol Rev 2011, 30:233-235.
• [19]Opioid abuse crackdown puts heroin back in style Available at: http://www.amednews.com/article/20130610/health/130619981/2/ webcite
• [20]Crozier MK, McMillan S, Hudson S, Jones S: The eastern north carolina opioid prescribers project: a model continuing medical education workshop. J Opioid Manag 2010, 6(5):359-364.
• [21]Proposed changes to Florida prescription drug database under fire Available at: http://www.palmbeachpost.com/news/news/state-regional-govt-politics/proposed-changes-to-florida-prescription-drug-data/nZdxP/ webcite
• [22]AMA Advocacy Resource Center: Drug Diversion and Prescription Drug Monitoring Programs. 2012. Available at: http://www.ama-assn.org/resources/doc/washington/issue-brief-prescription-drug-abuse-and-diversion.pdf webcite
• [23]Public Policy Statement on Measures to Counteract Prescription Drug Diversion, Misuse and Addiction Available at: http://www.asam.org/advocacy/find-a-policy-statement/view-policy-statement/public-policy-statements/2012/01/26/measures-to-counteract-prescription-drug-diversion-misuse-and-addiction webcite
• [24]American Medical Association: Issue brief: Rx drug abuse and diversion. AMA recommends a comprehensive approach to national crisis. 2013. Available at: http://www.ama-assn.org/resources/doc/washington/issue-brief-prescription-drug-abuse-and-diversion.pdf; webcite Accessed on 24 February 2013
• [25]Ostrom CM: New prescription monitoring draws complaints. USA: Seattle Times; 2012. Available at: http://seattletimes.com/html/localnews/2017147316_prescriptions04m.html webcite, accessed on 25 Feb 2014
• [26]Brogan D, Kelsall J: A harm reductionist response. Drug Alcohol Rev 2011, 30(3):330-331.
• [27]Institute of Medicine: Relieving Pain in America A Blueprint for Transforming Prevention, Care, Education, and Research Chronic. Washington, DC; 2011. Available at: http://www.iom.edu/~/media/Files/Report%20Files/2011/Relieving-Pain-in-America-A-Blueprint-for-Transforming-Prevention-Care-Education-Research/Pain%20Research%202011%20Report%20Brief.pdf webcite
• [28]Boscarino JA, Rukstalis MR, Hoffman SN, Han JJ, Erlich PM, Ross S, Gerhard GS, Stewart WF: Prevalence of prescription opioid-use disorder among chronic pain patients: comparison of the DSM-5 vs. DSM-4 diagnostic criteria. J Addict Dis 2011, 30(3):185-194.
• [29]Ling W, Mooney L, Hillhouse M: Prescription opioid abuse, pain and addiction: clinical issues and implications. Drug Alcohol Rev 2011, 30(3):300-305.
• [30]Clark T, Eadie J, Kreiner P, Strickler G: Prescription Drug Monitoring Programs: An Assessment of the Evidence for Best Practices. In The Prescription Drug Monitoring Program Center of Excellence. Brandeis University: Heller School for Social Policy and Management; 2012.
• [31]McDonald DC, Carlson KE: Estimating the prevalence of opioid diversion by “doctor shoppers” in the United States. PLoS One 2013, 8(7):e69241.
• [32]Blumenschein K, Fink J, Freeman P, James K, Kirsh K, Steinke DJT: Review of Prescription Drug Monitoring Programs in the United States: Independent Evaluation of the KASPER Program. Lexington, Kentucky: University of Kentucky; 2010.
• [33]Slevin KA, Ashburn MA: Primary care physician opinion survey on FDA opioid risk evaluation and mitigation strategies. J Opioid Manag 2011, 7(2):109-115.
• [34]Young A, Alfred KC, Davignon PP, Hughes LM, Robin LA, Chaudhry HJ: Physician survey examining the impact of an educational tool for responsible opioid prescribing. J Opioid Manag 2012, 8(2):81-87.
• [35]Dormuth CR, Miller TA, Huang A, Mamdani MM, Juurlink DN, Canadian Drug S, Effectiveness Research N: Effect of a centralized prescription network on inappropriate prescriptions for opioid analgesics and benzodiazepines. CMAJ 2012, 184(16):E852-856.
• [36]Silversides A: Australia moves to combat the misuse of prescription opioids. BMJ 2011, 342:d1345.
• [37]American Society of Addiction Medicine: Public Policy Statement on Measures to Counteract Prescription Drug Diversion, Misuse and Addiction. 2012. Available at: http://www.asam.org/advocacy/find-a-policy-statement/view-policy-statement/public-policy-statements/2012/01/26/measures-to-counteract-prescription-drug-diversion-misuse-and-addiction webcite
• [38]Report to the Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, House of Representatives: Prescription Drugs: State Monitoring Programs Provide Useful Tool to Reduce Diversion. United States General Accounting Office, Washington, D.C; 2002. Report: GAO-02-634
• [39]Green TC, Mann MR, Bowman SE, Zaller N, Soto X, Gadea J, Cordy C, Kelly P, Friedmann PD: How does use of a prescription monitoring program change medical practice? Pain Med 2012, 13(10):1314-1323.
• [40]Fischer B, Jones W, Krahn M, Rehm J: Differences and over-time changes in levels of prescription opioid analgesic dispensing from retail pharmacies in Canada, 2005–2010. Pharmacoepidemiol Drug Saf 2011, 20(12):1269-1277.
• [41]Simeone R, Holland L, Simeone Associates Inc: An Evaluation of Prescription Drug Monitoring Programs. Simeone Associates Inc; 2006. Available at: http://www.simeoneassociates.com/simeone3.pdf webcite
• [42]Fischer B, Jones W, Urbanoski K, Skinner R, Rehm J: Correlations between prescription opioid analgesic dispensing levels and related mortality and morbidity in Ontario, Canada, 2005–2011. Drug Alcohol Rev 2014, 33(1):19-26.
• [43]Larance B, Ambekar A, Azim T, Murthy P, Panda S, Degenhardt L, Mathers B: The availability, diversion and injection of pharmaceutical opioids in South Asia. Drug Alcohol Rev 2011, 30(3):246-254.
• [44]Hall W, Degenhardt L: Regulating opioid prescribing to provide access to effective treatment while minimizing diversion: an overdue topic for research. Addiction 2007, 102(11):1685-1688.